A literature review of cost-benefit analyses for the treatment of alcohol dependence

International Journal of Environmental Research and Public Health

Volumn 8, Issue 8, 2011, Pages 3351-3364

  Popova, Svetlana ^a,b   Mohapatra, Satya ^a   Patra, Jayadeep ^a,b   Duhig, Amy ^c   Rehm, Jürgen ^a,b,d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Alcohol dependence treatment; Benefits; Costs; Pharmacotherapy; Psychotherapy

Indexed keywords

ACAMPROSATE;

ALCOHOL ABSTINENCE; ALCOHOLISM; BEHAVIOR THERAPY; BELGIUM; COST BENEFIT ANALYSIS; COST CONTROL; COUNSELING; DRUG COST; HEALTH CARE COST; HUMAN; MARITAL THERAPY; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; SPAIN; UNITED STATES;

EID: 80052167987     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph8083351     Document Type: Review

References (34)

1. Cunningham, J.A.; Blomquist, J. Examining treatment use among alcohol-dependent individuals from a population perspective. Alcohol Alcohol. 2006, 41, 632-635.
2. Humphreys, K.; Moos, R. Can encouraging substance abuse patients to participate in self-help groups reduce demand for health care? A Quasi-experimental study. Alcohol. Clin. Exp. Res. 2001, 25, 711-716.
3. La Chance, H.; Feldstein, E.S.W.; Bryan, A.D.; Hutchison, K.E. What makes group motivational enhancement therapy (MET) work? A randomized controlled trial of college student drinkers in mandated alcohol diversion. Psychol. Addict. Behav. 2009, 23, 598-612.
4. Liddle, H.A.; Dakof, G.A.; Turner, R.M.; Henderson, C.E.; Greenbaum, P.E. Treating adolescent drug abuse: A randomized trial comparing multidimensional family therapy and cognitive behavior therapy. Addiction 2008, 103, 1660-1670.
5. Olive, M.F. Pharmacotherapies for alcoholism: The old and the new. CNS Neurol. Disord. Drug Targets 2010, 9, 2-4.
6. Williams, S.H. Medications for treating alcohol dependence. Am. Fam. Phys. 2005, 72, 1775-1780.
7. Anton, R.; O'Malley, S.; Ciraulo, D.; Cisler, R.; Couper, D.; Donovan, D.M.; Gastfriend, D.R.; Hosking, J.D.; Johnson, B.A.; LoCastro, J.S.; et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: A randomized controlled trial. JAMA 2006, 17, 2003-2017.
8. Bouza, C.; Angeles, M.; Munoz, A.; Amate, J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 2004, 99, 811-828.
9. Kranzler, H.R.; van Kirk, M. Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcohol. Clin. Exp. Res. 2001, 25, 1335-1341.
10. Garbutt, J.C.; Kranzler, H.R.; O'Malley, S.S.; Gastriend, D.R.; Pettinati, H.M. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA 2005, 293, 1617-1625.
11. Mann, K.; Lehert, P.; Morgan, M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcohol. Clin. Exp. Res. 2004, 28, 51-63.
12. Johnson, B.A.; Ait-Daoud, N.; Seneviratne, C.; Roache, J.D.; Javors, M.A.; Wang, X.Q.; Liu, L.; Penberthy, J.K.; DiClemente, C.C.; Li, M.D. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 2011, 168, 265-275.
13. Leggio, L.; Garbutt, J.C.; Addolorato, G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol. Disord. Drug Targets 2010, 9, 33-44.
14. Kranzler, H.R.; Armeli, S.; Tennen, H.; Covault, J.; Feinn, R.; Arias, A.J.; Pettinati, H.; Oncken, C. A double-blind, randomized trial of sertraline for alcohol dependence: Moderation by age and 5-hydroxytryptamine transporter-linked promoter region genotype. J. Clin. Psychopharmacol. 2011, 31, 22-30.
15. Pettinati, H.M.; Oslin, D.W.; Kampman, K.M.; Dundon, W.D.; Xie, H.; Gallis, T.L.; Dackis, C.A.; O'Brien, C.P. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am. J. Psychiatry 2010, 167, 668-675.
16. Litten, R.Z.; Fertig, J.; Mattson, M.E.; Egli, M. Development of medications for alcohol use disorders: Recent advances and ongoing challenges. Expert Opin. Emerging Drugs 2005, 10, 323-343.
17. Kraemer, K.L. The cost-effectiveness and cost-benefit of screening and brief intervention for unhealthy alcohol use in medical settings. Subst. Abus. 2007, 28, 67-77.
18. For Windows XP. Version 14. Minitab Inc.: State College, PA, USA, 2007.
19. O'Farrell, T.J.; Choquette, K.A.; Cutter, H.S.G.; Floyd, F.J.; Bayog, R.; Brown, E.D.; Lowe, J.; Chan, A.; Deneault, P. Cost-benefit and cost-effectiveness analyses of behavioral marital therapy as an addition to outpatient alcoholism treatment. J. Subst. Abus. 1996, 8, 145-166.
20. O'Farrell, T.J.; Choquette, K.A.; Cutter, H.S.G.; Brown, E.; Bayog, R.; McCourt, W.; Lowe, J.; Chan, A.; Deneault, P. Cost-benefit and cost-effectiveness analyses of behavioral marital therapy with or without relapse prevention sessions for alcoholics and their spouses. Behav. Ther. 1996, 27, 7-24.
21. Fleming, M.F.; Mundt, M.P.; French, M.T.; Manwell, L.B.; Stauffacher, E.A.; Barry, K.L. Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings. Med. Care 2000, 38, 7-18.
22. Fleming, M.F.; Mundt, M.P.; French, M.T.; Manwell, L.B.; Stauffacher, E.A.; Barry, K.L. Brief Physician advice for problem drinkers: Long term efficacy and benefit-cost analysis. Alcohol. Clin. Exp. Res. 2002, 26, 36-43.
23. Mundt, M.P.; French, M.T.; Roebuck, M.C.; Manwell, L.B.; Barry, K.L. Brief physician advice for problem drinking among older adults: An economic analysis of cost and benefits. J. Stud. Alcohol. 2005, 66, 389-394.
24. Mundt, M.P. Analyzing the costs and benefits of brief intervention. Alcohol. Res. Health 2006, 29, 34-36.
25. Gentilello, L.M.; Ebel, B.E.; Wickizer, T.M.; Salkever, D.S.; Rivara, F.P. Alcohol interventions for trauma patients treated in emergency departments and hospitals. Ann. Surg. 2005, 241, 541-550.
26. Annemans, L.; Vanoverbeke, N.; Tecco, J.; D'Hooghe, D. Economic evaluation of campral (acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. Eur. Addict. Res. 2000, 6, 71-78.
27. Portella, E.; Ridao, M.; Carrillo, E; Ribas, E.; Ribó, C.; Salvat, M. Alcohol y su abuso: Impacto Socio Económico; Editorial Medica Panamericana, S.A.: Madrid, Spain, 1998.
28. Poldrugo, F.; Haeger, D.A.; Comte, S.; Walburg, J.; Palmer, A. A critical review of pharmacoeconomic studies of acamprosate. Alcohol Alcohol. 2005, 40, 422-430.
29. Holder, H.D. Cost benefits of substance abuse treatment: An overview of results from alcohol and drug abuse. J. Ment. Health Policy Econ. 1998, 1, 23-29.
30. Kane, R.; Wall, M.; Potthoff, S.; Stromberg, K.; Dai, Y.; Meyer, Z. The effect of alcoholism treatment on medical care use. Med. Care 2004, 42, 395-402.
31. Swift, R.M. The pharmacotherapy of alcohol dependence: Clinical and economic aspects. Econ. Neurosci. 2001, 3, 62-66.
32. Kranzler, H.R. Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research. Alcohol Alcohol. 2002, 35, 537-547.
33. Graham, R.; Wodak, A.D.; Whelan, G. New pharmacotherapies for alcohol dependence. Med. J. Aust. 2002, 177, 103-107.
34. Carroll, K.M.; Kosten, T.R.; Rounsaville, B.J. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 2004, 75, 123-134.